The Hybridoma Facility performs the immunization of mice and rats, tests the sera, isolates splenocytes or lymph node lymphocytes and performs cell fusions to produce murine monoclonal antibodies (Mabs). Preparation of the purified or semi-purified antigens/proteins is the responsibility of individual laboratories. Simple screening of the resultant hybrid by ELISA are performed by facility personnel. The laboratory then provides help to individual investigators for more labor intensive screening and selection of antibodies. The laboratory has evolved into a highly interactive service that aims to train and educate investigators in hybridoma production and in preparing fluorochrome- and biotin-conjugated antibodies. The facility is located in Dr. Herlyn?s laboratory, which has an active research interest in Mab production. Projects are undertaken on a first-come, first-served basis. The facility charges $400 to $700 per antigen, depending on the nature and purity of the antigen, and the investigators are assured of at least one to two Mabs within three to four months.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA010815-34S2
Application #
6595919
Study Section
Project Start
2002-03-01
Project End
2003-02-28
Budget Start
Budget End
Support Year
34
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Schug, Zachary T (2018) Formaldehyde Detoxification Creates a New Wheel for the Folate-Driven One-Carbon ""Bi""-cycle. Biochemistry 57:889-890
Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Barbieri, Elisa; Trizzino, Marco; Welsh, Sarah Ann et al. (2018) Targeted Enhancer Activation by a Subunit of the Integrator Complex. Mol Cell 71:103-116.e7
Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:

Showing the most recent 10 out of 741 publications